HIV MAG pDNA vaccine / Profectus, National Institute of Allergy and Infectious Diseases - LARVOL DELTA

Acceptability and tolerability of repeated intramuscular electroporation of Multi-antigenic HIV (HIVMAG) DNA vaccine among healthy African participants in a phase 1 randomized controlled trial. (PubMed, PLoS One) - P1 | "Repeated intramuscular electroporation for vaccine delivery was found to be acceptable and feasible among healthy African HIV vaccine trial participants. The majority of participants reported an acceptable pain level at all vaccination time points. Further investigation may be warranted into the value of EP to improve immunization outcomes. ClinicalTrials.gov NCT01496989."

Clinical • Journal • P1 data • Gene Therapies • Human Immunodeficiency Virus • Infectious Disease • Pain

Therapeutic Vaccine for HIV (clinicaltrials.gov) - P1; N=33; Completed; Sponsor: National Institute of Allergy and Infectious Diseases (NIAID); Active, not recruiting ➔ Completed

Trial completion